New Interleukin Inhibitors May Give Stelara A Run For The Psoriasis Money
Executive Summary
Data showing IL-17 blockers Cosentyx and brodalumab beat J&J’s IL-12/23 inhibitor Stelara in psoriasis make a strong impression at the American Academy of Dermatology meeting, but that doesn’t necessarily mean they’ll be preferred.
You may also be interested in...
Valeant Gives Siliq Competitive Price In Crowded Psoriasis Market
The third IL-17 inhibitor on the US market will have a $3,500/month list price. But in a crowded, safety-conscious space like psoriasis, it's unclear how low the discounted price will need to go and whether competitive pricing would be enough to sway prescribers.
Sponsors Flesh Out Profiles of New Dermatology Drugs At AAD Meeting
Additional data for J&J's guselkumab, Regeneron/Sanofi's Dupixent, Lilly's Taltz and UCB/Dermira's Cimzia featured at the American Academy of Dermatology meeting in Orlando, Fla. March 3-7.
Indication-Based Pricing Could Be Windfall For Interleukin Inhibitors
Express Scripts' plan to reimburse at levels according to value of specific indications in inflammatory diseases will create more space for new entrants with proven value.